DEXA Body Composition: When to Order This Test

What DEXA Body Composition Actually Measures

A DEXA scan splits the body into three compartments: lean soft tissue, fat soft tissue, and bone mineral. The scanner fires two X-ray beams at different energy levels and calculates how much of each is absorbed by different tissue types. Research published in the Journal of Clinical Densitometry confirms that three-compartment DXA is the clinical reference standard for body composition in outpatient settings.

The Four Numbers That Matter Clinically

Lean mass (kg). This is skeletal muscle plus organ tissue. Clinicians focus specifically on appendicular lean mass (arms plus legs) because it predicts functional decline better than total lean mass.

Fat mass and body fat percentage. DEXA distinguishes subcutaneous fat from visceral fat. Visceral adipose tissue (VAT) is reported as a gram value or estimated area in cm² and carries independent cardiovascular risk beyond total body fat.

Bone mineral density (BMD). Reported as a T-score (comparison to young-adult peak) and Z-score (age-matched comparison). The WHO defines osteoporosis as a T-score at or below -2.5 at the femoral neck or lumbar spine (WHO 1994 diagnostic criteria, updated 2007).

Visceral adipose tissue (VAT). A VAT area above 100 cm² at L4-L5 is associated with insulin resistance, dyslipidemia, and elevated cardiovascular risk in multiple cohorts. A 2013 meta-analysis in Obesity Reviews (N=35 studies) found VAT was a stronger predictor of metabolic syndrome than BMI alone.

Why BMI Misses the Picture

BMI classifies weight relative to height. It cannot distinguish between 20 kg of fat and 20 kg of muscle. A 75 kg man with 15% body fat and 10 kg of visceral fat has a completely different risk profile than a 75 kg man with 28% body fat and 180 cm² of VAT, yet their BMI is identical. The Endocrine Society's 2023 obesity clinical practice guideline explicitly states that BMI alone is insufficient for diagnosing obesity-related disease and recommends body composition assessment as an adjunct.

When to Order a DEXA Body Composition Scan

Ordering criteria fall into four clinical categories. Each has different urgency and reorder intervals.

Category 1: GLP-1 and Weight-Loss Drug Monitoring

GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce substantial total weight loss, but a significant fraction of that loss may come from lean mass rather than fat. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021). Subgroup body composition analyses from STEP trials suggest roughly 25 to 39% of weight lost is lean tissue.

The SURMOUNT-1 trial (N=2,539) with tirzepatide 15 mg showed 20.9% mean weight loss at 72 weeks. Body composition sub-studies indicated that lean mass decline was dose-dependent and clinically meaningful at higher doses (Jastreboff et al., NEJM 2022).

Order a baseline DEXA before starting any GLP-1 agent. Reorder at 6 months to calculate the lean-mass preservation ratio. A patient losing weight with poor lean preservation (lean loss exceeding 30% of total weight lost) needs dietary protein optimization (1.2 to 1.6 g/kg/day) and resistance training before the next dose escalation.

Category 2: Sarcopenia Screening

The European Working Group on Sarcopenia in Older People (EWGSOP2) 2018 consensus defines probable sarcopenia by low grip strength or poor chair-stand performance, confirmed by low muscle mass on imaging. EWGSOP2 specifies DEXA ALMI cutoffs of <7.0 kg/m² in men and <5.5 kg/m² in women as diagnostic thresholds (Cruz-Jentoft et al., Age and Ageing 2019).

Screen with DEXA in:

• Adults over 60 with unintentional weight loss (>5% in 12 months)
• Adults of any age with type 2 diabetes on long-term therapy (metformin and SGLT2 inhibitors may each affect body composition)
• Patients with chronic kidney disease stage 3b or higher
• Postmenopausal women not on hormone therapy within the first 5 years after menopause
• Any patient with a SARC-F questionnaire score of 4 or higher

Category 3: Testosterone and Hormone Therapy Response Tracking

Testosterone replacement therapy (TRT) increases lean mass and reduces fat mass, but the magnitude varies by baseline body composition, hematocrit, and dosing method. A 2010 NEJM trial by Bhasin et al. (N=209) showed dose-dependent increases in lean mass (3.4 kg at 600 mg testosterone enanthate/week) and decreases in fat mass, with effects measurable on DEXA at 20 weeks.

For TRT patients, order DEXA at baseline and at 12 months. For women on estradiol-based HRT, DEXA serves double duty: it tracks lean-mass preservation and monitors BMD given the well-documented bone-protective effect of estrogen.

Category 4: Metabolic Disease Phenotyping

"Normal-weight obesity" affects roughly 30 million Americans. These patients have a BMI <25 but body fat percentage above 30% (women) or 25% (men), placing them at elevated cardiometabolic risk despite appearing lean by conventional metrics. A study in the European Heart Journal (Romero-Corral et al., N=6,171) found normal-weight obese individuals had 2.4-fold higher cardiovascular mortality than normal-weight, normal-fat individuals.

Order DEXA in any patient with:

• Fasting glucose 100 to 125 mg/dL with BMI <27
• Triglycerides above 150 mg/dL with no clear dietary explanation
• Non-alcoholic fatty liver disease (NAFLD) on imaging
• Insulin resistance confirmed by HOMA-IR >2.5

Normal DEXA Body Composition Ranges

Ranges differ by sex, age, and the specific manufacturer's reference database. The values below reflect NHANES-derived reference data used by GE Lunar and Hologic scanners.

Body Fat Percentage Reference Ranges

| Category | Men | Women | |---|---|---| | Essential fat | 2 to 5% | 10 to 13% | | Athlete | 6 to 13% | 14 to 20% | | Fit | 14 to 17% | 21 to 24% | | Acceptable | 18 to 24% | 25 to 31% | | Obese | >25% | >32% |

These cutoffs align with American College of Sports Medicine (ACSM) guidelines for body fat classification.

Appendicular Lean Mass Index (ALMI)

ALMI = (arm lean mass kg + leg lean mass kg) / height in m². Values below 7.0 kg/m² in men and 5.5 kg/m² in women meet EWGSOP2 criteria for low muscle mass. Values between the cutoff and 8.5 kg/m² (men) or 6.5 kg/m² (women) represent a borderline zone warranting repeat testing in 12 months.

Visceral Adipose Tissue (VAT)

VAT is reported in grams by most scanners. Clinical risk thresholds estimated from CT-validated DEXA correlations:

• <500 g (approximately <100 cm²): low cardiometabolic risk
• 500 to 1,000 g: moderate risk, warrants metabolic panel and lipid management
• >1,000 g: high risk, associated with non-alcoholic steatohepatitis and insulin resistance

A 2019 paper in Obesity (Neeland et al.) linked DEXA-measured VAT above 1,000 g to a 3.1-fold higher odds of metabolic syndrome compared to matched controls with VAT below 500 g.

What a High Body Fat Percentage on DEXA Means

A body fat percentage above the sex-specific "obese" threshold (25% men, 32% women) confirms excess adiposity regardless of BMI. The clinical significance depends on fat distribution, not just the total percentage.

Subcutaneous vs. Visceral Fat: Why Location Changes Everything

Subcutaneous fat (the fat you can pinch) is metabolically less active than VAT. Two patients can share identical total body fat percentages, one with most fat subcutaneous, one with most fat visceral, and have vastly different insulin sensitivity. DEXA's VAT estimate distinguishes these phenotypes without the radiation of a CT scan.

Actions for High Body Fat on DEXA

A body fat percentage above threshold should trigger:

1. Fasting insulin and HOMA-IR to quantify insulin resistance
2. Liver ultrasound if VAT exceeds 800 g to rule out hepatic steatosis
3. Nutrition assessment targeting a 500 to 750 kcal/day deficit with protein at or above 1.2 g/kg body weight
4. Resistance training prescription of at least 2 sessions per week targeting major muscle groups

If the patient is already on a GLP-1 agent and VAT remains high at 6 months, consider dose escalation (semaglutide from 1.7 mg to 2.4 mg, or tirzepatide from 10 mg to 15 mg) per prescribing guidelines, with a repeat DEXA at 12 months to confirm VAT reduction.

What a Low Lean Mass Score on DEXA Means

An ALMI below the sex-specific EWGSOP2 cutoff in the context of low grip strength (below 27 kg in men, below 16 kg in women) confirms sarcopenia. Sarcopenia is not simply a condition of older adults. It occurs in patients of any age who have experienced rapid weight loss, prolonged illness, or inadequate protein intake.

Sarcopenia and GLP-1 Therapy: A Specific Risk

Patients on semaglutide or tirzepatide who lose weight rapidly without structured resistance training may develop or worsen sarcopenia. A 2023 analysis in Diabetes, Obesity and Metabolism reported that patients on semaglutide who did not perform resistance exercise lost 1.8 kg more lean mass over 36 weeks than exercise-matched controls (Petermann-Rocha et al.).

The HealthRX Lean Mass Preservation Protocol for GLP-1 patients uses the following three-tier decision tree based on DEXA ALMI and rate of weight loss:

Tier 1 (ALMI normal, weight loss rate <1% per week). Continue current GLP-1 dose. Confirm dietary protein at 1.2 g/kg/day. Reorder DEXA in 6 months.

Tier 2 (ALMI borderline, weight loss rate 1 to 1.5% per week). Add structured resistance training, increase protein to 1.4 g/kg/day, consider creatine monohydrate 3 to 5 g/day, and reorder DEXA in 3 months before any dose escalation.

Tier 3 (ALMI below cutoff, weight loss rate >1.5% per week). Hold GLP-1 dose escalation. Refer to a registered dietitian for medical nutrition therapy. Consider testosterone evaluation (men) or estradiol assessment (women) if hormonal deficiency may be contributing. Repeat DEXA in 3 months.

Raising Lean Mass: What the Evidence Supports

The most effective interventions for increasing ALMI on repeat DEXA:

Resistance training. A meta-analysis in Sports Medicine (Peterson et al., N=1,079 older adults) found progressive resistance training increased lean mass by a mean of 1.1 kg over 20.5 weeks. Two to three sessions per week at 70 to 85% of one-rep maximum consistently outperformed lower-intensity protocols.

Protein intake. The PROT-AGE Study Group (Bauer et al., Journal of the Academy of Nutrition and Dietetics 2013) recommended 1.2 to 1.5 g/kg/day for older adults at risk of sarcopenia, noting that protein timing matters: 25 to 30 g per meal stimulates maximal muscle protein synthesis in most adults.

Testosterone optimization. In men with hypogonadism (total testosterone below 300 ng/dL confirmed on two morning samples), TRT reliably increases ALMI. The 2018 AUA guideline on testosterone deficiency supports this approach for symptomatic men with confirmed low testosterone. The Testosterone Trials (TTrials, N=790 men aged 65+) showed that testosterone gel 1% increased lean mass by 3.4 kg at 12 months compared to placebo (Snyder et al., NEJM 2016).

How Often to Repeat DEXA

Scan interval depends on the clinical question.

Monitoring Schedules by Indication

Active GLP-1 therapy. Every 6 months during dose escalation phase; every 12 months once at maintenance dose.

TRT or HRT initiation. Baseline before starting; repeat at 12 months. If BMD is normal and ALMI is improving, extend to every 24 months.

Established sarcopenia. Every 12 months while in active rehabilitation; every 24 months once ALMI has crossed above the diagnostic threshold on two consecutive scans.

Osteoporosis management. The USPSTF recommends BMD screening for all women 65 and older and for younger postmenopausal women with risk factors. For patients on bisphosphonates (alendronate 70 mg/week, risedronate 35 mg/week), repeat DEXA every 2 years to assess treatment response.

Metabolic phenotyping. Annual scan is adequate for patients with stable metabolic disease. Add a scan any time a patient begins or stops a medication known to affect body composition (glucocorticoids, aromatase inhibitors, SGLT2 inhibitors, GLP-1 agents).

Practical Steps Before and After the Scan

Before the Scan

• Fast for 3 hours (food and beverages affect soft-tissue water content and may shift lean-mass readings by 0.5 to 1.5 kg)
• Avoid strenuous exercise 24 hours before (acute exercise-induced glycogen loading increases intramuscular water)
• Use the same scanner model and software version at each visit if possible, Hologic and GE Lunar use different reference databases, and switching manufacturers introduces systematic error of 1 to 3%
• Remove metal objects and wear minimal clothing; avoid underwire bras

Interpreting the Report

The scan report will show total body fat %, regional fat distribution, ALMI, and T/Z-scores. Focus on trend over absolute value. A single DEXA is a cross-sectional snapshot. Two scans separated by at least 6 months give a rate-of-change that is clinically more actionable.

The International Society for Clinical Densitometry (ISCD) Official Positions on body composition state that the minimum detectable change for fat mass on DEXA is approximately 0.5 kg and for lean mass approximately 0.8 kg, meaning small changes within noise range should not drive major clinical decisions without corroborating clinical data.

GLP-1 Prescribers: A Checklist for DEXA Ordering

Patients starting semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) benefit most from DEXA when the following conditions are present:

• Starting BMI >30, or BMI >27 with at least one weight-related comorbidity (per FDA label criteria for Wegovy and Zepbound)
• Age 50 or older (higher baseline risk of sarcopenia)
• Pre-existing type 2 diabetes (muscle-wasting risk compounded by insulin resistance)
• Prior history of rapid weight loss (crash dieting, bariatric surgery, cancer)
• Grip strength below 30 kg (men) or 20 kg (women) at baseline

The American Association of Clinical Endocrinology (AACE) 2016 obesity management algorithm recommends body composition assessment as part of comprehensive evaluation for patients undergoing pharmacological weight management.

If all five conditions above are absent, a baseline DEXA is still reasonable but lower priority than fasting metabolic labs and a SARC-F screen.